Cargando…
Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi
Chagas disease caused by the protozoan parasite Trypanosoma cruzi is endemic in 21 Latin American countries and the southern United States and now is spreading into several other countries due to migration. Despite the efforts to control the vector throughout the Americas, currently, there are almos...
Autores principales: | Cerny, Natacha, Bivona, Augusto Ernesto, Sanchez Alberti, Andrés, Trinitario, Sebastián Nicolás, Morales, Celina, Cardoso Landaburu, Alejandro, Cazorla, Silvia Inés, Malchiodi, Emilio Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583359/ https://www.ncbi.nlm.nih.gov/pubmed/33162979 http://dx.doi.org/10.3389/fimmu.2020.565142 |
Ejemplares similares
-
Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
por: Bivona, Augusto E., et al.
Publicado: (2018) -
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection
por: Antonoglou, María Belén, et al.
Publicado: (2020) -
Activity of Estafietin and Analogues on Trypanosoma cruzi and Leishmania braziliensis
por: Sülsen, Valeria P., et al.
Publicado: (2019) -
Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
por: Sanchez Alberti, Andrés, et al.
Publicado: (2020) -
Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017)